Gabapentin Capsule
Product Images NDC 68788-8712

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8712). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules 300mg (Gabapentin 300mg 100s)

Label for Gabapentin Capsules 300 mg by Preferred Pharmaceuticals, Inc. The label indicates the product is a generic for Neurontin and each capsule contains 300 mg gabapentin. Manufacturer is ScieGen Pharmaceuticals, Inc. Directions are provided in English and Spanish. Storage instructions and caution notes appear on the label, but package size, expiration date, lot number, and other shipping details are blank.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain scores over 8 weeks for gabapentin 3600 mg/day compared to placebo. The x-axis indicates weeks divided into 4-week dose titration and 4-week fixed dose periods. Gabapentin scores decrease steadily over time, while placebo scores remain relatively stable.*

FDA Label Image

Figure 2 (Image 02)

Line graph showing mean pain scores over 7 weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, illustrating decreasing pain scores for both Gabapentin doses compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing results from two studies. The chart compares placebo (PBO) with Gabapentin (GBP) at different dosages. Study 1 displays 12% response for placebo and 29% for GBP 3600 mg; Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values below 0.01 and 0.001.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula depicting creatinine clearance calculation (CLCr) involving age, weight, serum creatinine, and an adjustment factor for female patients. The equation is presented as [(140 - age in years) x weight in kg] divided by [72 x serum creatinine in mg/dL], multiplied by 0.85 for females.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin showing a cyclohexane ring attached to an aminomethyl group and an acetic acid group, representing the molecular arrangement of the active ingredient gabapentin.*

FDA Label Image

Image-09 (Image 09)

A scatter plot chart showing the relationship between daily dose (mg) on the x-axis and difference (%) on the y-axis. The chart compares three studies labeled as Study a, Study b, and Study c, with data points indicated by distinct square markers for each study across multiple dose levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.